Table 3.
Patient (N = 17) | Age (y) | CR duration (mo) | Cause of death | Response at time of death | Comments |
---|---|---|---|---|---|
1 | 69 | 69.9 | Stage IV GIST | CR | |
2 | 77 | 8 | Prostate cancer | CR | |
3 | 75 | 60 | Prostate cancer | CR | |
4 | 60 | 96.2 | H&N cancer | CR | |
5 | 47 | 4.9 | Prostate cancer | CR | |
6 | 64 | 77.5 | Melanoma | CR | |
7 | 74 | 73.4 | Pancreatic cancer | CR | |
8 | 70 | 16.5 | Melanoma | CR | |
9 | 69 | 58.4 | ESRD on HD | CR | Renal biopsy showed glomerulosclerosis. Pt had DM. |
10 | 75 | 15.7 | ESRD on HD | CR | Received 1 cycle. Therapy discontinued because of fluid overload and worsening creatinine. Pt had other comorbidities including CHF, DM, and HTN. |
11 | 38 | 9 | Pneumococcal meningitis | CR | Pt was 644 D post-SCT and was off immunosuppression. Pt had hepatic insufficiency. |
12 | 64 | 0.9 | Sepsis/pneumonia | CR | s/p 2 cycles, sepsis unrelated to study drugs. Pt had DM and HTN. |
13 | 21 | 9.3 | Infection and pulmonary embolism | CR | Patient was treated with ATRA/ATO/GO on protocol for 2.5 mo and achieved CR but taken off protocol because of ATRA intolerance; ATO/GO off protocol: for 2 mo; IDA off protocol: C3 D59 |
14 | 69 | 7 | CHF and cardiac arrest | CR | C3 D31 on protocol. Pt had history of CAD s/p bypass surgery, HTN, and hyperlipidemia. |
15 | 81 | 25.2 | Unknown | CR | Lost to follow-up |
16 | 81 | 106.8 | Unknown | CR | Lost to follow-up |
17 | 43 | 39.2 | Unknown | CR | Lost to follow-up |
C, cycle; CHF, congestive heart failure; D, day; DM, diabetes mellitus; ESRD, end-stage renal disease; GIST, gastrointestinal stromal tumor; HD, hemodialysis: H&N, head and neck; HTN, hypertension; mo, month; Pt, patient; s/p, status post.